Sun Pharma acquires fellow Indian drugmaker for $4B

Daiichi Sankyo agreed to sell Ranbaxy Laboratories to fellow Indian generic drugmaker Sun Pharmaceutical Industries for $4 billion in an all-stock deal. The combined entity will become the fifth-biggest generic-drug firm in the world and the largest biopharmaceutical company in India. "We see tremendous growth opportunities and are excited with the prospects to create lasting value for both our shareholders through a successful combination of our franchises," Sun Pharma Managing Director Dilip Shanghvi said.

View Full Article in:

Genetic Engineering & Biotechnology News · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations